As potential blood biomarkers, VIP and aCGRP may be considered of great advantage since they would be easily standardized, may link between pulmonary and non-pulmonary complications of CF, and they may acutely change in response to treatment, thus providing rapid insight into therapeutic outcomes. The gene discussed is VIP; the disease is cystic fibrosis.